Form 4 for BIIB Biogen
Accepted 2024-02-09 00:00:00 ET · period of report 2024-02-07 · accession 0001127602-24-004304 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-09 | 2024-02-08 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | +2,101 | 7,895 | +36% | $0 |
| D | 2024-02-09 | 2024-02-08 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | F - Tax | $240.30 | -638 | 7,257 | -8% | -$153.3K |
| D | 2024-02-09 | 2024-02-08 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | -2,101 | 4,204 | -33% | $0 |
| D | 2024-02-09 | 2024-02-07 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | A - Grant | $0.00 | +5,820 | 5,820 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-08 | M | A | 2,101 | $0.00 | 7,894.99 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-08 | F | D | 638 | $240.30 | 7,256.99 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2024-02-08 | M | D | 2,101 | $0.00 | 4,204 | D | $0.00 · — to 2026-02-08 | 2,101 Common Stock | (F2) The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023. |
| 4 | Derivative | Restricted Stock Unit | 2024-02-07 | A | A | 5,820 | $0.00 | 5,820 | D | $0.00 · — to 2027-02-07 | 5,820 Common Stock | (F1) The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. |